Skip to main content

New Analysis Reveals Most Patients Discontinue Weight Loss Drugs Within First Year

By: PRLog
PreventiveMedicineDaily.com Publishes Comprehensive Review on GLP-1 Medication Persistence Rates Despite Long-Term Treatment Recommendations

FRESNO, Calif. - Jan. 11, 2026 - PRLog -- PreventiveMedicineDaily.com has published a comprehensive analysis revealing that despite being designed for long-term use, most patients discontinue GLP-1 weight loss medications within the first year of treatment. The detailed review, supervised by Jose Rossello, MD, PhD, MCHM, examines real-world persistence data from 2024-2025 and highlights a significant gap between clinical recommendations and patient adherence patterns.

According to the comprehensive analysis published in "How Long Are People on Weight Loss Drugs?", only 40-63% of patients remain on GLP-1 medications at 12 months, with persistence rates dropping to approximately 15-25% at two years. The review examined multiple medications including semaglutide versus tirzepatide, and liraglutide (Saxenda), finding that once-weekly formulations demonstrate better persistence than daily injections. At the six-month mark, approximately 47% of patients remain on treatment, representing a critical period when many face challenges with side effects, cost, or insurance coverage changes.

"This disconnect between recommended long-term use and actual patient persistence raises important questions about treatment expectations, affordability, and support systems," according to the PreventiveMedicineDaily.com analysis. The review emphasizes that clinical guidelines recommend GLP-1 medications as chronic disease management tools with no maximum duration restrictions, yet real-world data consistently shows early discontinuation followed by significant weight regain in most patients.

The analysis identifies multiple factors contributing to early discontinuation, including medication costs averaging $900-$1,300 per month without insurance, gastrointestinal side effects, and widespread misperceptions of GLP-1 medications as short-term solutions. The review also highlights that newer medications like tirzepatide show improved persistence rates (55-73% at six months) compared to earlier GLP-1 formulations.

"Understanding real-world persistence patterns is essential for patients and healthcare providers to set realistic expectations and plan for long-term success," notes the PreventiveMedicineDaily.com editorial team. "Our goal is to provide evidence-based information that helps readers make informed decisions about preventive care and weight management strategies."

Related articles:

Natural GLP-1 Boosters

What Tea Is Best for Weight Loss

Caloric Needs Calculator (Interactive tool)


Contact
Jose Rossello (Owner)
Preventive Medicine Daily
***@preventivemedicinedaily.com

Photos: (Click photo to enlarge)

Weight Loss Medication Retention Rates


Source: Preventive Medicine Daily

Read Full Story - New Analysis Reveals Most Patients Discontinue Weight Loss Drugs Within First Year | More news from this source

Press release distribution by PRLog

Recent Quotes

View More
Symbol Price Change (%)
AMZN  239.12
+0.94 (0.39%)
AAPL  255.53
-2.68 (-1.04%)
AMD  231.83
+3.91 (1.72%)
BAC  52.97
+0.38 (0.72%)
GOOG  330.34
-2.82 (-0.85%)
META  620.25
-0.55 (-0.09%)
MSFT  459.86
+3.20 (0.70%)
NVDA  186.23
-0.82 (-0.44%)
ORCL  191.09
+1.24 (0.65%)
TSLA  437.50
-1.07 (-0.24%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.